Ampio Stock Jumps On Enrollment Expansion Of Mid-Stage COVID-19 Trial To India With Inhaled Ampion

  • Ampio Pharmaceuticals Inc AMPE has received regulatory approval to expand enrollment of its AP-019 Phase 2 study to India, assessing inhaled Ampion to treat those suffering from respiratory distress due to COVID-19.
  • The company said that amid political unrest in Israel and the surrounding region combined with the reduction in COVID cases, it would discontinue the AP-019 study in Israel and instead reallocate the resources to India and other potential select territories outside the U.S., depending on the ongoing magnitude of COVID-19 cases.
  • In April, the company reported the earlier Phase 1 study results that showed that Ampion reduced all-cause mortality in COVID-19 respiratory distress by 78% over the Standard of Care (SOC) for COVID-19 respiratory distress.
  • Specifically, mortality in the SOC group was 24%, while in the group treated with Ampion, mortality was only 5%.
  • Price Action: AMPE shares are up 16.7% at $2.10 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareSmall CapFDAGeneralBriefsCovid-19COVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!